Skip to main content
Delfa

← Trials/Trial dossier/NCT02500784

WithdrawnPhase 2

Improving Beta-2 Adrenergic Signaling in Alzheimer's Disease

Asset

Formoterol A

Listed sites

1

Recruiting sites

-

Enrollment

-

actual

Study population

Alzheimer’s disease

Key I/E criteria

•mild-to-moderate AD•MMSE 16-26

Primary endpoints

•Cognition Evaluation•Brain-derived neurotrophic factor (BDNF) Evaluation

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDASJ0015
NCT IDNCT02500784

Timeline

Milestones

Study first posted2015-07-17estimated
Last update posted2020-09-16actual
Study start2023-01estimated (month precision)
Primary completion2025-04estimated (month precision)
Study completion2025-07estimated (month precision)

Assets

Drug assets

Formoterol A

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age50 Years
Maximum age85 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Males and females between the ages of 50-85,
•Mild-to-moderate AD (NINCDS/ADRDA criteria for probable AD will be used to establish AD diagnosis).
•MMSE 16-26

Exclusion criteria

•Non-AD dementia or significant neurological disease such as Parkinson's disease, stroke, brain tumor,multiple sclerosis, seizure disorder, focal brain lesion, or head injury with loss of consciousness.
•Hypothyroidism, congestive heart failure (New York Heart Association Class III or IV), significant extrapyramidal symptoms on neurological examination, serum creatinine>1.3 mg/dl, significant arrhythmias or conduction defect abnormalities on ECG,
•Use of another beta2 adrenergic drug within the last 2 months.
•Residence in a long-term care facility.
•Evidence of any significant clinical disorder or laboratory finding that renders the person unsuitable for receiving an investigational new drug.
•Known hypersensitivity or prior exposure to formoterol.
•Active asthma or family history of asthma.

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
2
Amyloid biomarkers
1

Amyloid biomarkers

1 endpoint
Secondary/protocol endpoint

Amyloid accumulation

Time frame:Baseline and month 16

descriptive

Other (unclassified)

2 endpoints
Primary/protocol endpoint/low confidence

Cognition Evaluation

Time frame:1 Month

descriptive

Primary/protocol endpoint/low confidence

Brain-derived neurotrophic factor (BDNF) Evaluation

Time frame:Baseline and month 16

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.